{"id":32716,"date":"2025-07-09T16:03:34","date_gmt":"2025-07-09T10:33:34","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=32716"},"modified":"2025-07-09T16:03:35","modified_gmt":"2025-07-09T10:33:35","slug":"efgartigimod-for-nmosd-and-mogad","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/efgartigimod-for-nmosd-and-mogad","title":{"rendered":"EAN 2025: Efgartigimod Add-on Shows Promising Efficacy in NMOSD and MOGAD during Acute Relapse"},"content":{"rendered":"\n<ul class=\"wp-block-list\">\n<li><em>Adjunctive efgartigimod with intravenous methylprednisolone (IVMP) <\/em><strong><em>led to greater EDSS improvement<\/em><\/strong><em> and rapid IgG reduction in patients with acute NMOSD and MOGAD.<\/em><\/li>\n\n\n\n<li><em>Intensive dosing (<\/em><strong><em>20\u202fmg\/kg \u00d7 2) produced faster neurological recovery<\/em><\/strong><em> and greater antibody titer reductions.<\/em><\/li>\n<\/ul>\n\n\n\n<p>At <strong>EAN 2025<\/strong>, new data highlighted the potential of <strong>efgartigimod<\/strong>, a <strong>neonatal Fc receptor<\/strong> (FcRn) inhibitor, as an add-on to intravenous methylprednisolone (IVMP) for patients experiencing acute attacks of <strong>Neuromyelitis Optica Spectrum Disorder<\/strong> (NMOSD) and <strong>Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease<\/strong> (MOGAD)\u2014two rare but debilitating autoimmune demyelinating conditions driven by pathogenic IgG autoantibodies.<\/p>\n\n\n\n<p>In this exploratory study of 27 adult patients (13 on efgartigimod + IVMP; 14 on IVMP alone), efgartigimod was administered intravenously 10mg\/kg \u00d7 4 doses or 20mg\/kg \u00d7 2 doses. Adjunctive efgartigimod led to significantly <strong>greater neurological improvement<\/strong>, with a mean reduction in Expanded Disability Status Scores (EDSS) of <strong>1.3\u202f\u00b1\u202f0.6 vs. 0.5\u202f\u00b1\u202f0.5<\/strong> in the control group. Biologically, the therapeutic impact was underscored by a marked <strong>69.8% decrease in total serum IgG<\/strong> and <strong>antibody titer reduction<\/strong> in nearly <strong>70%<\/strong> of treated patients\u2014suggesting efgartigimod\u2019s mechanism of reducing circulating pathogenic antibodies translated into meaningful clinical benefit.<\/p>\n\n\n\n<p>Notably, patients receiving the more intensive dosing regimen (<strong>20\u202fmg\/kg\u202f\u00d7\u202f2<\/strong>) experienced <strong>faster and more pronounced improvements in both EDSS scores and antibody titers<\/strong>. Safety was acceptable, with no new safety signals observed, supporting the tolerability of FcRn blockade in the acute setting.<\/p>\n\n\n\n<p>These findings reinforce FcRn antagonism as a mechanistically targeted strategy for immunoglobulin-mediated CNS disorders and pave the way for larger, controlled trials to define the role of efgartigimod in both NMOSD and MOGAD relapse management.<\/p>\n\n\n\n<p><strong>KOL Views<\/strong><\/p>\n\n\n\n<p>The introduction of FcRn blockers like efgartigimod represents a significant advance in the acute management of NMOSD and MOGAD. Early clinical results are encouraging, particularly for patients who do not respond adequately to steroids alone. However, larger controlled studies are required. <strong>\u2013 Expert Opinion<\/strong><\/p>\n\n\n\n<p>While efgartigimod and similar biologics are reshaping the treatment landscape for antibody-mediated CNS disorders, careful patient selection and biomarker-driven monitoring will be key. <strong>\u2013 Expert Opinion<\/strong><\/p>\n\n\n\n<p><strong>Conclusion<\/strong>Efgartigimod, an FcRn inhibitor, shows substantial promise as an add-on therapy to IVMP for acute NMOSD and MOGAD. Clinical data indicate that efgartigimod leads to a <strong>greater reduction in disability (as measured by EDSS), a significant decrease in pathogenic antibody titers, and a rapid decline in serum IgG levels<\/strong> compared to IVMP alone. The therapy is well-tolerated, with no serious adverse events reported in the available studies. However, the current evidence is limited by small sample sizes and short follow-up periods, and larger, randomized controlled trials are needed to confirm both the long-term efficacy and safety of efgartigimod in these patient populations.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>At EAN 2025, new data highlighted the potential of efgartigimod, a neonatal Fc receptor (FcRn) inhibitor, as an add-on to intravenous methylprednisolone (IVMP) for patients experiencing acute attacks of Neuromyelitis Optica Spectrum Disorder (NMOSD) and Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)\u2014two rare but debilitating autoimmune demyelinating conditions driven by pathogenic IgG autoantibodies. In this exploratory [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":32718,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17126],"tags":[22601],"industry":[17225],"therapeutic_areas":[17245],"class_list":["post-32716","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-others","tag-ean-annual-congress","industry-pharmaceutical","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Efgartigimod for NMOSD and MOGAD | EAN 2025<\/title>\n<meta name=\"description\" content=\"Efgartigimod, an FcRn inhibitor, shows substantial promise as an add-on therapy to IVMP for acute NMOSD and MOGAD.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/efgartigimod-for-nmosd-and-mogad\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Efgartigimod for NMOSD and MOGAD | EAN 2025\" \/>\n<meta property=\"og:description\" content=\"Efgartigimod, an FcRn inhibitor, shows substantial promise as an add-on therapy to IVMP for acute NMOSD and MOGAD.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/efgartigimod-for-nmosd-and-mogad\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-09T10:33:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-09T10:33:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/09160327\/efgartigimod-for-nmosd-and-mogad.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Efgartigimod for NMOSD and MOGAD | EAN 2025","description":"Efgartigimod, an FcRn inhibitor, shows substantial promise as an add-on therapy to IVMP for acute NMOSD and MOGAD.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/efgartigimod-for-nmosd-and-mogad","og_locale":"en_US","og_type":"article","og_title":"Efgartigimod for NMOSD and MOGAD | EAN 2025","og_description":"Efgartigimod, an FcRn inhibitor, shows substantial promise as an add-on therapy to IVMP for acute NMOSD and MOGAD.","og_url":"https:\/\/www.delveinsight.com\/blog\/efgartigimod-for-nmosd-and-mogad","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-07-09T10:33:34+00:00","article_modified_time":"2025-07-09T10:33:35+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/09160327\/efgartigimod-for-nmosd-and-mogad.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/efgartigimod-for-nmosd-and-mogad","url":"https:\/\/www.delveinsight.com\/blog\/efgartigimod-for-nmosd-and-mogad","name":"Efgartigimod for NMOSD and MOGAD | EAN 2025","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/efgartigimod-for-nmosd-and-mogad#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/efgartigimod-for-nmosd-and-mogad#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/09160327\/efgartigimod-for-nmosd-and-mogad.png","datePublished":"2025-07-09T10:33:34+00:00","dateModified":"2025-07-09T10:33:35+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Efgartigimod, an FcRn inhibitor, shows substantial promise as an add-on therapy to IVMP for acute NMOSD and MOGAD.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/efgartigimod-for-nmosd-and-mogad"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/efgartigimod-for-nmosd-and-mogad#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/09160327\/efgartigimod-for-nmosd-and-mogad.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/09160327\/efgartigimod-for-nmosd-and-mogad.png","width":466,"height":284,"caption":"efgartigimod-for-nmosd-and-mogad"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/09160327\/efgartigimod-for-nmosd-and-mogad-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Others<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Others<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">EAN Annual Congress<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">EAN Annual Congress<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 10 months ago","modified":"Updated 10 months ago"},"absolute_dates":{"created":"Posted on Jul 9, 2025","modified":"Updated on Jul 9, 2025"},"absolute_dates_time":{"created":"Posted on Jul 9, 2025 4:03 pm","modified":"Updated on Jul 9, 2025 4:03 pm"},"featured_img_caption":"efgartigimod-for-nmosd-and-mogad","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32716","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=32716"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32716\/revisions"}],"predecessor-version":[{"id":32719,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32716\/revisions\/32719"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/32718"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=32716"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=32716"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=32716"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=32716"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=32716"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}